EUVIMEDEUVIMED entdecken
Crossref

Features of therapeutic options for the treatment of non-alcoholic fatty liver disease and carbohydrate metabolism disorders

N.A. Petunina, M.Е. Теlnova, E.V. Goncharova, I.A. Kuzina

Lechaschi Vrach · 20.05.2026 · (5(29))

DOI: 10.51793/os.2026.29.5.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lechaschi Vrach, erschienen am 20.05.2026. Verfasst von N.A. Petunina und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetes mellitus is one of the most common diseases worldwide, and non-alcoholic fatty liver disease is recognized as the most common chronic liver disease worldwide. According to current clinical guidelines, non-alcoholic (metabolic dysfunction-associated) steatotic liver disease is a chronic liver condition characterised by macrovesicular steatosis involving at least 5% of hepatocytes. In 75% of cases, non-alcoholic fatty liver disease occurs in the presence of obesity, dyslipidemia, hypertension, type 2 diabetes mellitus, or impaired glucose tolerance. A consistent "bidirectional association" of pathophysiological, epidemiological, and clinical characteristics has been demonstrated between non-alcoholic fatty liver disease and type 2 diabetes. The comorbidity of type 2 diabetes mellitus and non-alcoholic steatotic liver disease doubles the risk of cardiovascular diseases, confers a 2-2.5-fold increased risk of cirrhosis and hepatocellular carcinoma, as well as a 22-fold excess risk of liver-related mortality, compared with the general population. Insulin resistance is a leading factor in the development of non-alcoholic fatty liver disease. Evidence has accumulated indicating that intestinal microflora, bile acid metabolism, and autophagy contribute to the pathogenesis of non-alcoholic fatty liver disease. Clinical manifestations of non-alcoholic fatty liver disease are often absent or mild. In real-world clinical practice, patients present to physicians with complaints related to comorbid conditions associated with non-alcoholic fatty liver disease. Modern approaches to non-alcoholic fatty liver disease treatment are aimed at preventing liver disease progression, regressing steatosis, steatohepatitis, and fibrosis, and reducing cardiometabolic risk factors. It is known that there is a close relationship between non-alcoholic fatty liver disease and carbohydrate metabolism disorders, based on common etiopathogenetic factors.

Conclusion

A multifaceted approach to managing patients with non-alcoholic fatty liver disease and type 2 diabetes, using ursodeoxycholic acid, can be recommended for all forms of non-alcoholic fatty liver disease. At the same time, weight management, physical activity, and dietary changes are effective measures not only for preventing the development of non-alcoholic fatty liver disease but also for reducing the risk of developing and progressing cardiometabolic disorders.

Zitieren

APA

Petunina, N., Теlnova, M., Goncharova, E., & Kuzina, I. (2026). Features of therapeutic options for the treatment of non-alcoholic fatty liver disease and carbohydrate metabolism disorders. Lechaschi Vrach. https://doi.org/10.51793/os.2026.29.5.002

Vancouver

Petunina N, Теlnova M, Goncharova E, Kuzina I. Features of therapeutic options for the treatment of non-alcoholic fatty liver disease and carbohydrate metabolism disorders. Lechaschi Vrach. 2026. doi:10.51793/os.2026.29.5.002

BibTeX
@article{Petunina2026,
  author = {Petunina, N.A. and Теlnova, M.Е. and Goncharova, E.V. and Kuzina, I.A.},
  title = {Features of therapeutic options for the treatment of non-alcoholic fatty liver disease and carbohydrate metabolism disorders},
  journal = {Lechaschi Vrach},
  year = {2026},
  number = {5(29)},
  doi = {10.51793/os.2026.29.5.002}
}
Kostenlos starten →